Cargando…

A pathogenic IFNα, BLyS and IL-17 axis in Systemic Lupus Erythematosus patients

This study aims to analyze in depth the role of IFNα in the upregulation of BLyS in different leukocyte populations and the possible relationship of these molecules with IL-17 and other pathogenic cytokines in SLE. Thus, IFNAR1 and membrane BLyS (mBLyS) expression was upregulated on various blood ce...

Descripción completa

Detalles Bibliográficos
Autores principales: López, Patricia, Rodríguez-Carrio, Javier, Caminal-Montero, Luis, Mozo, Lourdes, Suárez, Ana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4742957/
https://www.ncbi.nlm.nih.gov/pubmed/26847824
http://dx.doi.org/10.1038/srep20651
_version_ 1782414279330234368
author López, Patricia
Rodríguez-Carrio, Javier
Caminal-Montero, Luis
Mozo, Lourdes
Suárez, Ana
author_facet López, Patricia
Rodríguez-Carrio, Javier
Caminal-Montero, Luis
Mozo, Lourdes
Suárez, Ana
author_sort López, Patricia
collection PubMed
description This study aims to analyze in depth the role of IFNα in the upregulation of BLyS in different leukocyte populations and the possible relationship of these molecules with IL-17 and other pathogenic cytokines in SLE. Thus, IFNAR1 and membrane BLyS (mBLyS) expression was upregulated on various blood cell types from patients and closely correlated in all individuals. Moreover, BLyS serum levels associated positively with IFNα and IL-17A amounts, as well as with mBLyS on B cells and neutrophils. Interestingly, mBLyS on neutrophils was also correlated with IL-17A levels. Additionally, intracellular IL-17A expression was increased in both CD4(+) lymphocytes and neutrophils from patients, and IL-17(+)CD4(+) T cell frequency was associated with serum IFNα and IFNRA1 expression on B cells. Finally, in vitro assays support an IFNα role in the activation of Th17 cells in SLE. In conclusion, these data suggest that IFNα, BLyS and IL-17 could form a pathological axis in SLE, involving T and B lymphocytes, monocytes, DCs and neutrophils, which act in a vicious circle that encourage the preexisting inflammation and propagate the disease process.
format Online
Article
Text
id pubmed-4742957
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-47429572016-02-09 A pathogenic IFNα, BLyS and IL-17 axis in Systemic Lupus Erythematosus patients López, Patricia Rodríguez-Carrio, Javier Caminal-Montero, Luis Mozo, Lourdes Suárez, Ana Sci Rep Article This study aims to analyze in depth the role of IFNα in the upregulation of BLyS in different leukocyte populations and the possible relationship of these molecules with IL-17 and other pathogenic cytokines in SLE. Thus, IFNAR1 and membrane BLyS (mBLyS) expression was upregulated on various blood cell types from patients and closely correlated in all individuals. Moreover, BLyS serum levels associated positively with IFNα and IL-17A amounts, as well as with mBLyS on B cells and neutrophils. Interestingly, mBLyS on neutrophils was also correlated with IL-17A levels. Additionally, intracellular IL-17A expression was increased in both CD4(+) lymphocytes and neutrophils from patients, and IL-17(+)CD4(+) T cell frequency was associated with serum IFNα and IFNRA1 expression on B cells. Finally, in vitro assays support an IFNα role in the activation of Th17 cells in SLE. In conclusion, these data suggest that IFNα, BLyS and IL-17 could form a pathological axis in SLE, involving T and B lymphocytes, monocytes, DCs and neutrophils, which act in a vicious circle that encourage the preexisting inflammation and propagate the disease process. Nature Publishing Group 2016-02-05 /pmc/articles/PMC4742957/ /pubmed/26847824 http://dx.doi.org/10.1038/srep20651 Text en Copyright © 2016, Macmillan Publishers Limited http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
spellingShingle Article
López, Patricia
Rodríguez-Carrio, Javier
Caminal-Montero, Luis
Mozo, Lourdes
Suárez, Ana
A pathogenic IFNα, BLyS and IL-17 axis in Systemic Lupus Erythematosus patients
title A pathogenic IFNα, BLyS and IL-17 axis in Systemic Lupus Erythematosus patients
title_full A pathogenic IFNα, BLyS and IL-17 axis in Systemic Lupus Erythematosus patients
title_fullStr A pathogenic IFNα, BLyS and IL-17 axis in Systemic Lupus Erythematosus patients
title_full_unstemmed A pathogenic IFNα, BLyS and IL-17 axis in Systemic Lupus Erythematosus patients
title_short A pathogenic IFNα, BLyS and IL-17 axis in Systemic Lupus Erythematosus patients
title_sort pathogenic ifnα, blys and il-17 axis in systemic lupus erythematosus patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4742957/
https://www.ncbi.nlm.nih.gov/pubmed/26847824
http://dx.doi.org/10.1038/srep20651
work_keys_str_mv AT lopezpatricia apathogenicifnablysandil17axisinsystemiclupuserythematosuspatients
AT rodriguezcarriojavier apathogenicifnablysandil17axisinsystemiclupuserythematosuspatients
AT caminalmonteroluis apathogenicifnablysandil17axisinsystemiclupuserythematosuspatients
AT mozolourdes apathogenicifnablysandil17axisinsystemiclupuserythematosuspatients
AT suarezana apathogenicifnablysandil17axisinsystemiclupuserythematosuspatients
AT lopezpatricia pathogenicifnablysandil17axisinsystemiclupuserythematosuspatients
AT rodriguezcarriojavier pathogenicifnablysandil17axisinsystemiclupuserythematosuspatients
AT caminalmonteroluis pathogenicifnablysandil17axisinsystemiclupuserythematosuspatients
AT mozolourdes pathogenicifnablysandil17axisinsystemiclupuserythematosuspatients
AT suarezana pathogenicifnablysandil17axisinsystemiclupuserythematosuspatients